




RealRate

PHARMACEUTICAL 2014

Lixte Biotechnology Holdings INC
Rank 204 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lixte Biotechnology Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lixte Biotechnology Holdings INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 9.9% points. The greatest weakness of Lixte Biotechnology Holdings INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 104%, being 139% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	558
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	322
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0.0030
Other Revenues	0
Property and Equipment	0
Research and Development	880
Selling, General and Administrative Expense	495

Output Variable	Value in 1000 USD
Assets	558
Liabilities	322
Expenses	1,375
Revenues	0
Stockholders Equity	236
Net Income	-1,375
Comprehensive Net Income	-1,375
BaseVar	1,127
ECR before LimitedLiability	-195%
Economic Capital Ratio	104%